National Project on Vaccines, COVID-19 and Frail Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- COVID-19
- "Hematologic Diseases"
- Neurologic Disorder
- Rheumatic Diseases
- Solid Tumor
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The immune response to COVID-19 vaccination will be assessed at the following time points: T0: the day of vaccination T1: the day of the booster dose according to the schedule of the two vaccines (Pfizer/BioNTech or Moderna) T2: between 5 and 7 weeks after T0 for those vaccinated with Pfizer/BioNTec...
The immune response to COVID-19 vaccination will be assessed at the following time points: T0: the day of vaccination T1: the day of the booster dose according to the schedule of the two vaccines (Pfizer/BioNTech or Moderna) T2: between 5 and 7 weeks after T0 for those vaccinated with Pfizer/BioNTech and between 6 and 8 weeks after T0 for those vaccinated with Moderna. T3: 12 (± 1) weeks after T0 T4: 24 (± 2) weeks from T0 T5: 52 (± 2) weeks from T0 Prevention of SARS-CoV-2 infection will be assessed in terms of incidence of SARS-CoV-2 infections (NF molecular swab positive), and of SARS-CoV-2 infections requiring hospitalisation.
Tracking Information
- NCT #
- NCT04848493
- Collaborators
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Istituto Clinico Humanitas
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- IRCCS San Raffaele
- Regina Elena Cancer Institute
- Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS
- University of Roma La Sapienza
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Istituti Fisioterapici Ospitalieri
- Istituto Tumori Giovanni Paolo II, BARI
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- Investigators
- Principal Investigator: Massimo Costantini Azienda USL-IRCCS di Reggio Emilia
Get Well Soon